Digital Biomarkers Market Size 2025 Expands with 22.74% CAGR with North America Leading at 59% Global Share

Ottawa, July 14, 2025 (GLOBE NEWSWIRE) -- The global digital biomarkers market size was valued at USD 4.15 billion in 2024 and is predicted to hit around USD 32.37 billion by 2034, a study published by Towards Healthcare a sister firm of Precedence Research.

The growth of the market is driven by the growing demand for wearable devices, biosensors, desktop software, mobile apps, and many more from which industry drives the growth of the market.

Explore market dynamics, key drivers, and regional insights with our free sample report on the digital biomarkers market: https://www.towardshealthcare.com/download-sample/5434

Key Takeaways

North America dominated the digital biomarkers market share by 59% in 2024.
Asia-Pacific is anticipated to grow at the fastest rate in the market during the forecast period.
By system component, the data collection tools segment registered its dominance over the global market in 2024.
By system component, the data integration systems segment is predicted to witness significant growth in the market over the forecast period.
By application, the cardiovascular disease segment held the largest share of the digital biomarkers market in 2024.
By application, the respiratory disease segment is estimated to grow at the fastest rate in the market during the forecast period.
By clinical practice, the diagnostic digital biomarkers segment led the global market in 2024.
By clinical practice, the monitoring digital biomarkers segment is anticipated to grow with the highest CAGR in the market during the studied years.
By end-use, the healthcare companies segment held a dominant presence in the digital biomarkers market in 2024.
By end-use, the payers segment is projected to expand rapidly in the market in the coming years.

Market Overview & Potential

Digital biomarkers are objective and measurable physiological and behavioral data collected via digital devices such as wearables, smartphones, and other sensors. They help explain, influence, or predict health outcomes by offering real-time insights into a person's health. Examples include heart rate, sleep patterns, and activity levels, which are tracked by wearables to evaluate cardiovascular health, sleep quality, and physical activity.

Gait and speech patterns can also be digitally measured to detect or monitor neurological conditions like Parkinson's disease. Digital assessments of cognitive processing speed and memory assist in identifying cognitive decline, such as in Alzheimer's disease. Additionally, continuous glucose monitoring (CGM) systems track blood sugar levels in real time for diabetes management with technology.

Access detailed segmentation statistics, CAGR trends, and forecast figures in our comprehensive digital biomarkers market databook: https://www.towardshealthcare.com/download-databook/5434

What Are the Key Growth Factors Responsible for The Growth of The Digital Biomarkers Market?

Digital biomarkers are mainly fueled by the widespread use of wearable and smart devices such as smartwatches, fitness trackers, and mobile health apps. Key drivers include data-driven insights, consumer engagement, advancements in healthcare technology like cloud integration and AI, digital therapeutics and diagnostics, improved data analysis, and the rising need for personalized and remote patient monitoring. Cost-effectiveness and patient empowerment also play crucial roles.

These factors increase data availability, which, when combined with AI and machine learning, improve healthcare delivery and decision-making, leading to market growth and expansion. Additionally, factors like the growing prevalence of chronic diseases, an aging population, and increased digitalization in healthcare support further adoption and market expansion.

What are the Growing Trends Associated with the digital biomarkers market?

Integration Of AI and Machine Learning

The integration of AI and ML for optimization and to analyze data for wearables and other digital devices for more active and personalized healthcare solutions.

Personalized and Preventive Healthcare

The digital biomarkers play a crucial role in remote patient monitoring, which allows continuous tracking of patient health and also helps in early detection.

Advancements In Wearable Technology

The advancements in wearable technology for enhancing the wider range of physiologic and behavioral data to create a comprehensive digital biomarker solution.

Use In Drug Development and Clinical Trials

To improve efficiency and identify digital endpoints and to stratify the patient population the digital biomarkers are extensively used in clinical trials and drug development.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

What is the Growing Challenge in the digital biomarkers market?

The key challenge responsible for the hindrance in the growth of the market is the commercialization and adoption of the market. The high development costs of developing a digital biomarker are a challenge due to limited adoption in the price-sensitive market and are a barrier for commercialization and especially for small companies, which limit the growth of the market. Securing returns on investments and integrating them into healthcare is also another challenge in the market, which limits the growth and expansion of the market.

Regional Analysis

How did North America Dominate the digital biomarkers market in 2024?

North America dominated the market share by 59% in 2024. The growth of the market is driven by the rising adoption of technology in the region, especially in the healthcare sector for analysis and optimization, and for enhancing the experience drives the growth of the market in the region.

The growth is also driven by the growing use of digital technology for the management of chronic diseases, and also to regulate the healthcare problems associated with the treatment, and also track the patient health record, which increases the adoption of the market and also supports the growth and expansion of the market in the region.

In the U.S., digital biomarkers are increasingly used in clinical trials, remote patient monitoring, and chronic disease management. Integration with wearables and mobile apps enables real-time health tracking. Healthcare providers and researchers are adopting them for early diagnosis, personalized treatment, and continuous assessment of neurological, cardiovascular, and metabolic conditions.

In Canada, digital biomarkers are increasingly employed in academic and clinical settings to integrate wearable-sensor data into population health studies, monitoring physical activity, sleep, and cardiovascular metrics. Universities like Alberta use smartwatches to track ALS remotely, enabling real-time, decentralized disease monitoring and personalized interventions.

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

What made Asia Pacific Significantly Grow in the digital biomarkers market in 2024?

Asia-Pacific is anticipated to grow at the fastest rate in the market during the forecast period. The growth of the market is driven by the rising adoption of wearables due to growing awareness about the diseases and health concerns associated, which demands for real-time tracking system, which increases the demand for the market in the region and fuels the growth.

The young awareness and healthcare expenditure due to the rising prevalence of chronic diseases also contribute to the growth of the market due to increasing adoption. The rapid advancements in technology and demand for more innovative and enhanced remote monitoring are the factors that drive the growth and expansion of the market in the region.

In China, digital biomarkers are increasingly leveraged in government-supported telehealth programs, AI-driven diagnostics, and wearable medical devices. Hospitals, tech firms (e.g., Huawei, Xiaomi), and startups integrate sensors for continuous monitoring of vital signs, chronic diseases, and cancer recovery. These tools empower remote care, early detection, and personalized disease management.

In India, digital biomarkers are widely used in decentralized clinical trials and remote monitoring via wearables, enabling continuous physiological tracking outside clinics. Notably, continuous glucose monitors (CGMs) like FreeStyle Libre empower real-time diabetes management, reducing HbA1c and guiding personalized therapy

Elevate your healthcare strategy with Towards Healthcare. Enhance efficiency and drive better outcomes schedule a call today: https://www.towardshealthcare.com/schedule-meeting

Segmental Insights

By system component

How Did Data Collection Tools Segment Dominate the Digital Biomarkers Market In 2024?

The data collection tools segment registered its dominance over the global market in 2024. Data collection tools form the backbone of the market by enabling the continuous and accurate gathering of physiological and behavioral data from individuals. These tools include wearable devices, mobile applications, smart sensors, and remote monitoring systems that capture vital signs, movement patterns, sleep quality, and more. By providing real-time, high-frequency data, they support early disease detection, personalized treatment adjustments, and proactive health management. Their integration into clinical workflows empowers researchers and healthcare providers to make data-driven decisions and enhance patient engagement.

The data integration systems segment is predicted to witness significant growth in the digital biomarkers market over the forecast period. Data integration systems are essential for the effective use of digital biomarkers, as they consolidate and harmonize data from diverse sources such as wearables, mobile apps, electronic health records, and laboratory results.

These systems ensure that complex, large-scale data is accurately processed, analyzed, and transformed into actionable insights for clinicians and researchers. By enabling a comprehensive view of patient health, data integration systems support personalized treatment plans, improve clinical decision-making, and facilitate seamless collaboration across different healthcare stakeholders, ultimately enhancing patient outcomes.

By application

Which Application Segment Dominated the Digital Biomarkers Market In 2024?

The cardiovascular disease segment held the largest share of the market in 2024. The growth of the market is driven by the increasing prevalence of cardiovascular diseases, which creates a strong demand for innovative diagnostic and monitoring tools.

Additionally, rising healthcare expenditure and advancements in digital health technologies in smart wearables, mobile applications, and sensors that track vital signs and activity metrics drive the demand for the market. The rising heart conditions demand personalized and preventive healthcare for monitoring and management of cardiovascular diseases through active plans and disease management drives the growth of the market.

The respiratory disease segment is estimated to grow at the fastest rate in the digital biomarkers market during the forecast period. The growth of the market is driven by the increasing prevalence of respiratory diseases and illness post covid which demands effective and advanced monitoring, increasing the demand for the market.

The demand for effective monitoring and management due to rising pollution also increases the prevalence of respiratory diseases, which increases demand for advanced digital health technologies for remote and continuous monitoring and tracking of data for early detection and personalized treatment, fueling the growth of the market.

By clinical practice

How Did Diagnostic Digital Biomarkers Segment Dominate the Digital Biomarkers Market In 2024?

The diagnostic digital biomarkers segment led the global market in 2024. Diagnostic digital biomarkers play a crucial role in transforming healthcare by enabling early and accurate detection of diseases through digital tools. These biomarkers, collected via wearable devices, smartphone apps, or sensors, provide continuous, real-time physiological and behavioral data. Their ability to detect changes before clinical symptoms appear supports preventive care and personalized treatment approaches. Additionally, they improve patient monitoring, reduce reliance on invasive tests, and aid clinicians in making data-driven diagnostic decisions, ultimately enhancing patient outcomes.

The monitoring digital biomarkers segment is anticipated to grow with the highest CAGR in the market during the studied years. Monitoring digital biomarkers is revolutionizing the way chronic and acute conditions are managed by enabling continuous, real-time tracking of a patient’s health status outside clinical settings.

Collected through smart wearables, mobile apps, and connected devices, these biomarkers provide valuable insights into disease progression and treatment response. By allowing clinicians to detect deviations from normal patterns early, they support timely intervention, enhance patient adherence, and promote personalized care plans, ultimately improving long-term health outcomes and reducing healthcare costs.

By end-use

Which End Use Segment Dominated the Digital Biomarkers Market in 2024?

The healthcare companies segment held a dominant presence in the market in 2024. Healthcare companies are increasingly adopting digital biomarkers to enhance patient care, accelerate drug development, and improve clinical outcomes. By leveraging data from wearables, sensors, and mobile apps, these companies can gather real-time insights into patients' physiological and behavioral health.

This helps in early disease detection, monitoring treatment responses, and personalizing therapies. Additionally, integrating digital biomarkers supports remote patient monitoring and chronic disease management, enabling healthcare providers to offer more efficient, data-driven, and patient-centered care while reducing operational costs.

The payers segment is projected to expand rapidly in the digital biomarkers market in the coming years. Payers, including insurance companies and government health programs, are adopting digital biomarkers to improve risk assessment, optimize resource allocation, and control healthcare costs.

By utilizing continuous, real-time health data from wearables and connected devices, payers can more accurately evaluate patient health trends and predict potential complications, increasing the demand. This proactive approach enables early intervention, reduces hospital admissions, and supports value-based care models. Furthermore, digital biomarkers help payers design personalized wellness programs, incentivize healthy behaviors, and enhance overall population health outcomes effectively.

Recent Developments

In December 2024, electronRx, a prominent digital medicine and biomarker firm advancing healthcare via pulmonary innovation, announced the launch of purpleDx, a cardiopulmonary assessment app conforming to medical device standards, at CES 2025 in Las Vegas, USA. This technology allows chronic respiratory disease (CRD) patients to detect and track digital lung function biomarkers at home, while offering clinicians real-time data to tailor treatments and enhance patient outcomes.

Top Companies and Their Contributions to the Market

Company	Contributions & Offerings in Digital Biomarkers
Roche Holding AG	Develops digital health tools like remote patient monitoring and wearable-integrated platforms for disease tracking.
Bio-Rad Laboratories	Offers digital PCR and genomics tools supporting biomarker discovery and validation in clinical diagnostics.
AliveCor	Specializes in ECG monitoring via Kardia devices; provides AI-powered heart health biomarkers via mobile platforms.
Biogen	Collaborates with tech firms to develop digital biomarkers for neurological diseases like Alzheimer’s and MS.
IXICO	Provides digital imaging biomarkers and analytics for neurodegenerative disease trials using AI and MRI data.
Koneksa	Develops wearable-integrated platforms to collect real-world data and validate digital biomarkers for pharma trials.
Thermo Fisher Scientific	Supplies high-throughput genomic and proteomic tools aiding digital biomarker research and validation.
Agilent Technologies	Offers precision measurement and data platforms for biomarker analysis in diagnostics and life sciences.
Epigenomics AG	Focuses on blood-based epigenetic biomarkers, especially for early cancer detection using digital quantification.
Fitbit Inc	Tracks physiological metrics (e.g., heart rate, sleep) used to identify digital biomarkers for chronic conditions.

Browse More Insights of Towards Healthcare:

The global women’s digital health market was valued at USD 3.17 billion in 2024 and grew to USD 3.82 billion in 2025. It is expected to reach around USD 20.92 billion by 2034, growing at a CAGR of 20.54%.
The Asia-Pacific women’s digital health market was worth USD 724.17 million in 2024 and increased to USD 889.14 million in 2025. It is projected to reach about USD 5.69 billion by 2034, with an annual growth rate of 22.74%.
The Europe women’s digital health market was valued at USD 1.03 billion in 2024 and is estimated to reach USD 1.24 billion in 2025. By 2034, it could grow to USD 6.69 billion at a CAGR of 20.24%.
The global digital healthcare education market was valued at USD 53.67 billion in 2024 and rose to USD 58.2 billion in 2025. It is forecasted to reach around USD 120.67 billion by 2034, growing annually at 8.44%.
The global digital mental health market was USD 27.84 billion in 2024 and increased to USD 33.01 billion in 2025. It is expected to grow to USD 153.03 billion by 2034, with a CAGR of 18.58%.
The global digital therapeutics market was valued at USD 7.7 billion in 2024 and is expected to reach USD 9.84 billion in 2025. It is projected to hit around USD 90.83 billion by 2034, expanding at a CAGR of 27.8%.
The global digital pathology market reached USD 1.14 billion in 2024 and grew to USD 1.23 billion in 2025. It is expected to reach USD 2.51 billion by 2034, growing at a rate of 8.24% per year.
The global digital psychotherapeutics market was valued at USD 1.69 billion in 2024 and increased to USD 2.17 billion in 2025. It is projected to grow to USD 20.66 billion by 2034, at a CAGR of 28.24%.
The global healthcare ERP market stood at USD 7.99 billion in 2024 and reached USD 8.57 billion in 2025. It is likely to grow to USD 16.06 billion by 2034, at an annual rate of 7.23%.
The global digital breast tomosynthesis market was USD 3.03 billion in 2024 and rose to USD 3.45 billion in 2025. It is estimated to reach USD 10.89 billion by 2034, expanding at a CAGR of 13.63%.

Top Key players in Digital Biomarkers Market

Roche Holding AG
Bio-Rad Laboratories
AliveCor
Biogen
IXICO
Koneksa
Thermo Fisher Scientific
Agilent Technologies
Epigenomics AG
Fitbit Inc
Akili Interactive Labs
ALTODA AG
Kinsa
Merck KGaA
Siemens Healthineers
Huma

Segments Covered in the Report

By System Component

Data Collection Tools
Mobile Apps
Wearable
Digital Platforms
Biosensors
Desktop-Based Software
Data Integration Systems

By Application

Sleep & Movement Disease
Cardiovascular Diseases
Respiratory Disease
Neurodegenerative Disorders
Diabetes
Gastrointestinal Disease
Psychiatric Disorder
Others

By Clinical Practice

Diagnostic Digital Biomarkers
Monitoring Digital Biomarkers
Predictive And Prognostic Digital Biomarkers
Others (Safety, Pharmacodynamics/ Response, Susceptibility)

By End-use

Healthcare Companies
Healthcare Providers
Payers
Others (Patients, caregivers)

By Region

North America
- U.S.
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
Latin America
- Brazil
- Mexico
- Argentina
Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait

Get the complete strategic analysis, company profiles, and market forecasts in the full report on the global digital biomarkers market: https://www.towardshealthcare.com/price/5434

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Our Trusted Data Partners

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.